Holen Sie sich die Stockscreener-App
15.47
1.91%
0.29
Vorhandelsmarkt:
15.12
-0.35
-2.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
(AUPH) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aurinia Pharmaceuticals Doubles Down On Its Pipeline (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Navigating Growth in Biotech with a 10% Upside Potential - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance - simplywall.st
Aurinia Pharmaceuticals Announces Q2 2026 Financial Results with Strong Revenue and Income Growth - Kalkine Media
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28— 10-Q Summary - TradingView
AUPH: Strong revenue and profit growth fueled by LUPKYNIS sales and disciplined capital allocation - TradingView
Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance - TradingView
Aurinia Q2 revenue rises 19 percent to $83.2 million - Quiver Quantitative
AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook - TradingView
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress - Caledonian Record
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M - moomoo.com
BRIEF-Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million - TradingView
Aurinia Pharma earnings beat by $0.05, revenue topped estimates - Investing.com Canada
(AUPH) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Uncovering a 16.68% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain - simplywall.st
Lazard Asset Management LLC Sells 106,820 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc Revenue Breakdown – NASDAQ:AUPH - TradingView
Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharma earnings up next as growth momentum faces test By Investing.com - Investing.com UK
OMERS ADMINISTRATION Corp Takes Position in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
AUPH Q2'26 Earnings: EPS estimate is 0.24 USD - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Strong Growth Potential with an 11.7% Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Sells 102,826 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
AUPH|Aurinia Pharmaceuticals Inc|Price:15.215|Chg%:-0.135 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:14.880|Chg%:-0.120 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Balance Sheet - TradingKey
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a shareEarnings Preview - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aurinia Pharmaceuticals Inc. Revenue Breakdown – LS:A1W7D4 - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Institutional Confidence - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:15.350|Chg%:+0.110 - TradingKey
AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160 - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Cash Flow - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AUPH Q2'26 Earnings: revenue estimate is 80.45M USD - TradingView
Liquidity Mapping Around (AUPH) Price Events - Stock Traders Daily
Zacks Research Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Hold - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Aurinia Pharmaceuticals Inc (AUPH) Fundamental & Financial Data - Stocktwits
Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary - Quartr
Aurinia Pharmaceuticals (AUPH) Proxy filing Summary - Quartr
Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary - Quartr
Aurinia Pharmaceuticals (AUPH) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Aurinia Pharmaceuticals (AUPH) Q4 2024 earnings summary - Quartr
Aurinia Pharmaceuticals (AUPH) Q4 2025 earnings summary - Quartr
Aurinia Pharmaceuticals (AUPH) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Investors - Aurinia Pharmaceuticals Inc.
bullish divergence on the hourly has held above support at 15.50, i like the stock 😀 - Moomoo
Price to earnings forward of Aurinia Pharmaceuticals Inc. – SWB:IKAP - TradingView
Is Aurinia Pharmaceuticals (AUPH) Using Combination LN Trials to Redefine Its LUPKYNIS Strategy? - Sahm
Price to earnings forward of Aurinia Pharmaceuticals Inc. – MUN:IKAP - TradingView
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca
Aurinia launches trial combining lupus nephritis treatments - Investing.com
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):